Retatrutide
Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors developed by Eli Lilly. Its clinical-trial progress and regulatory status are tracked on this page from official sources.
- Editorial attention
- Building
- Tracked this week
- 4
- Sources this week
- 3
- Last activity
- 9 hrs ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Retatrutide at a glance
- About this topic
- Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors developed by Eli Lilly. Its clinical-trial progress and regulatory status are tracked on this page from official sources.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis (opens the source in a new tab) (Rapid communications in mass spectrometry : RCM, Oct 1, 2026)
- Key facts from tracked records
- 20 clinical trials tracked from ClinicalTrials.gov
What’s the latest on Retatrutide?
0 totalNo briefings on this topic yet. Official records and trials below are updated continuously.
What do the official records show?
Primary sources and peer-reviewed researchWhich clinical trials are being tracked?
All trials- Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Eli Lilly and Company. Conditions: Diabetes Mellitus, Type 2. Investigational — not approved for the use studied.
- TRIUMPH-7: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly and Company. Conditions: Obesity; Overweight; Chronic Low Back Pain (CLBP). Investigational — not approved for the use studied.
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company. Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD). Investigational — not approved for the use studied.
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company. Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease. Investigational — not approved for the use studied.
- TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company. Conditions: Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea. Investigational — not approved for the use studied.
- Pre-approval Expanded Access of Retatrutide (LY3437943)
Eli Lilly and Company. Conditions: Obesity; Obesity-related Complications. Investigational — not approved for the use studied.
Industry coverage
Headlines link to the original publication- #EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold (opens the source in a new tab)
- #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes (opens the source in a new tab)
- Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity (opens the source in a new tab)